Szekeres, Z.; Sandor, B.; Bognar, Z.; Ramadan, F.H.J.; Palfi, A.; Bodis, B.; Toth, K.; Szabados, E.
Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. Int. J. Mol. Sci. 2023, 24, 4405.
https://doi.org/10.3390/ijms24054405
AMA Style
Szekeres Z, Sandor B, Bognar Z, Ramadan FHJ, Palfi A, Bodis B, Toth K, Szabados E.
Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. International Journal of Molecular Sciences. 2023; 24(5):4405.
https://doi.org/10.3390/ijms24054405
Chicago/Turabian Style
Szekeres, Zsolt, Barbara Sandor, Zita Bognar, Fadi H. J. Ramadan, Anita Palfi, Beata Bodis, Kalman Toth, and Eszter Szabados.
2023. "Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes" International Journal of Molecular Sciences 24, no. 5: 4405.
https://doi.org/10.3390/ijms24054405
APA Style
Szekeres, Z., Sandor, B., Bognar, Z., Ramadan, F. H. J., Palfi, A., Bodis, B., Toth, K., & Szabados, E.
(2023). Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. International Journal of Molecular Sciences, 24(5), 4405.
https://doi.org/10.3390/ijms24054405